 7. Evidence of tumor DNA showing either NRAS mutation or NRAS WTBRAF WT. BRAF genotype must be determined by a CLIA-approved assay. NRAS genotyping may be determined by Sanger sequencing, melting point PCR assay, Sequenome, or NextGen sequencing. 